Camurus concludes Phase II trial of CAM2029 to treat NETs

Swedish-based pharmaceutical company Camurus has concluded the Phase II study of CAM2029 to treat acromegaly or neuroendocrine tumours (NETs).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsBecause dental anomalies, especially radiculomegaly, are a primary feature of OFCD syndrome, dentists should be aware of the clinical and radiographic features. Radiculomegaly poses a distinct challenge to dentists, and reports of dental therapy provided to these patients are sparse. Early diagnosis of the syndrome may prevent dental challenges and improve prognosis.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
This study was undertaken to analyze the effects of transsphenoidal surgery (TSS) on acromegalic arthropathy and elucidate whether knee MRI findings are reversible or irreversible. We analyzed 22 patients with acromegaly (63.7% females, median age 58 years) by knee MRI at diagnosis. Out of these 22 patients, 16 who underwent TSS (68.9% female, median age 58 years) were also subjected to knee MRI 2 months after TSS. As for X-ray undetectable findings, MRI detected synovial thickening, bone marrow lesion, ligament injury and meniscus injury in 22.7%, 22.7%, 4.7% and 59.1% of the patients, respectively. With respect to the 16...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
Anca Zimmermann, R üdiger Zwerenz, Michael Droste, Christof Schöfl, Christian J. Strasburger, Ursula Plöckinger, Athanasia Ziagaki, Jürgen Honegger, Anne Dixius, Bledar Millaku, Gerrit Toenges, Manfred E. Beutel, Matthias M. Weber
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
ConclusionsRT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences.
Source: Journal of Neuroradiology - Category: Radiology Source Type: research
Publication date: April 2018Source: Best Practice &Research Clinical Endocrinology &Metabolism, Volume 32, Issue 2Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. StratakisX-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
We report here the first case of a patient with an undiagnosed MAS presenting with an acute hydrocephalus. A 21-year-old male with gigantism and craniofacial fibrous dysplasia consulted for rapidly progressive headache. An acute obstructive hydrocephalus due to a 39  × 35-mm cystic lesion in the third ventricle was discovered and operated, obtaining hydrocephalus resolution. Pathology described a colloid cyst material and a growth hormone-secreting pituitary adenoma. Genetic study revealed the mosaic GNAS R201H mutation in the pituitary tissue, confirming a MAS diagnosis. Adequate hormonal control was a...
Source: Virchows Archiv - Category: Pathology Source Type: research
Francesco Ferra ù, Adriana Albani, Alessandro Ciresi, Carla Giordano, Salvatore Cannavò
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: The majority of the surveyed physicians reported variable adherence to the international acromegaly guidelines. Clearly, higher awareness is needed among physicians for early diagnosis and timely referral for specialist management. PMID: 29971605 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
ConclusionsRT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences.
Source: Journal of Neuroradiology - Category: Radiology Source Type: research
Publication date: April 2018Source: Best Practice &Research Clinical Endocrinology &Metabolism, Volume 32, Issue 2Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. StratakisX-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
More News: Acromegaly | Neurology | Pharmaceuticals | Study